Tango Therapeutics (TNGX) Competitors

Arbutus Biopharma (NASDAQ:ABUS) and Tango Therapeutics (NASDAQ:TNGX) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, institutional ownership, profitability, media sentiment, analyst recommendations, community ranking, earnings, valuation and risk.

Is ABUS or TNGX more profitable?

Tango Therapeutics has a net margin of -284.42% compared to Arbutus Biopharma's net margin of -1,137.65%. Tango Therapeutics' return on equity of -49.64% beat Arbutus Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Arbutus Biopharma	-1,137.65%	-68.18%	-51.55%
Tango Therapeutics	-284.42%	-49.64%	-32.00%

Does the media favor ABUS or TNGX?

In the previous week, Tango Therapeutics had 1 more articles in the media than Arbutus Biopharma. MarketBeat recorded 6 mentions for Tango Therapeutics and 5 mentions for Arbutus Biopharma. Tango Therapeutics' average media sentiment score of 1.34 beat Arbutus Biopharma's score of 0.90 indicating that Tango Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Arbutus Biopharma	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Tango Therapeutics	4 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Does the MarketBeat Community prefer ABUS or TNGX?

Arbutus Biopharma received 407 more outperform votes than Tango Therapeutics when rated by MarketBeat users. However, 74.36% of users gave Tango Therapeutics an outperform vote while only 70.66% of users gave Arbutus Biopharma an outperform vote.

Company	Underperform	Outperform
Arbutus Biopharma	Outperform Votes 436 70.66%	Underperform Votes 181 29.34%
Tango Therapeutics	Outperform Votes 29 74.36%	Underperform Votes 10 25.64%

Do insiders and institutionals have more ownership in ABUS or TNGX?

43.8% of Arbutus Biopharma shares are held by institutional investors. Comparatively, 79.0% of Tango Therapeutics shares are held by institutional investors. 20.3% of Arbutus Biopharma shares are held by insiders. Comparatively, 6.3% of Tango Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Which has more volatility & risk, ABUS or TNGX?

Arbutus Biopharma has a beta of 1.45, indicating that its share price is 45% more volatile than the S&P 500. Comparatively, Tango Therapeutics has a beta of 1.03, indicating that its share price is 3% more volatile than the S&P 500.

Do analysts prefer ABUS or TNGX?

Arbutus Biopharma currently has a consensus target price of $5.50, indicating a potential upside of 54.28%. Tango Therapeutics has a consensus target price of $12.33, indicating a potential upside of 765.50%. Given Tango Therapeutics' higher possible upside, analysts plainly believe Tango Therapeutics is more favorable than Arbutus Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arbutus Biopharma	0 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	3.00
Tango Therapeutics	0 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	3.00

Which has higher earnings & valuation, ABUS or TNGX?

Arbutus Biopharma has higher earnings, but lower revenue than Tango Therapeutics. Arbutus Biopharma is trading at a lower price-to-earnings ratio than Tango Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arbutus Biopharma	$6.17M	110.62	-$72.85M	-$0.38	-9.38
Tango Therapeutics	$42.07M	3.66	-$101.74M	-$1.21	-1.18

Summary

Tango Therapeutics beats Arbutus Biopharma on 11 of the 17 factors compared between the two stocks.